Design of a recombinant immunotoxin against the human granulocyte-colony stimulating factor receptor
- 39 Downloads
Immunotoxin is a new strategy for protein therapy of cancer. This engineered protein contains two parts, the immune part which is an antibody or cytokine, directed against the cancer cell receptor, and the toxin part consisting of a plant or bacterial toxin leading to apoptosis by protein synthesis inhibition. The knowledge of cell-surface receptor overexpression in cancer cells can help scientists to construct new anti-cancer agents. The granulocyte colony stimulating factor (G-CSF) receptor is expressed on the cell surface of some blood cancers such as acute myeloid leukemia (AML). Therefore, this receptor can be used as an immunotoxin for treatment of some cancers. The aim of this work was to design and produce DT-GCSF immunotoxin using truncated DT fused to G-CSF. For fusion protein construction, DT389 and G-CSF fragments, were amplified by PCR using specific primers. A flexible linker SerGly4SerMet (SG4SM) was used to fuse the PCR products by SOEing PCR procedure to achieve an appropriate fusion protein, and the fused fragment was subcloned into pET21b. The new construction (pET-DT389GCSF) was transformed into E. coli strain BL21 (DE3) and the expression of the construction was confirmed by SDS-PAGE and Western blotting techniques. The data demonstrated the expression and purity rates of DT389GCSF about 25% and 90%, respectively. This chimeric protein construction can be used as a new anti-AML drug, but its in vitro and in vivo biological activity should be analyzed.
KeywordsDiphtheria toxin Immunotoxin Granulocyte colony-stimulating factor Expression Purification
We would like to thank the Department of Bioscience and Biotechnology, Malek-Ashtar University of Technology for financial support of this project.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research was not involved in the human participants and/or animals.
- 4.Wu HC, Chang DK, Huang CT (2006) Targeted therapy of cancer. J Cancer Mol 2(2):57–66Google Scholar
- 11.Reiter Y (2001)) Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 124:81–93Google Scholar
- 18.Amraei M, Zeinoddini M, Solimani M, Saeedinia AR (2015) Cloning, expression, purification and toxicity assessment of diphtheria toxin-interleukin2 fusion protein. Iran J Pol Med 4(2):105–113Google Scholar
- 19.Fallah MJ, Akbari B, Saeedinia AR, Karimi M, Vaez M, Zeinoddini M et al (2003) Overexpression of recombinant human granulocyte colony stimulating factor in E.coli. Iran J Med Sci 28(3):131–134Google Scholar